In April 2026, the United States Food and Drug Administration (FDA) announced the approval of a new medication, orforglipron (Foundayo™), for reducing excess body weight and maintaining that reduction over the long term. What is orforglipron (Foundayo™)? It is a new GLP-1 receptor agonist developed by Eli Lilly and Company. My guess is that the “glip” in…